



Epidemiology Of Patients
Revascularized For Peripheral Artery
Disease in France (2016-19): A
Retrospective Observational Cohort
Study Using The French Hospital
Discharge Database (PMSI)

Victor Aboyans, MD, PhD

1) Department of Cardiology, Dupuytren University Hospital, Draveil, France


2) INSERM 1094 & IRD, University of Limoges, 2, France

Dr Victor Aboyans

I have the following potential conflicts of interest to report:

Fees from: Alliance Boehringer Ingelheim/Lilly, Amarin Pharma, Inc., AstraZeneca, Vifor Pharma


- Peripheral artery disease (PAD) is common
- The most severe cases require revascularization
- Recently: Voyager-PAD trial



ORIGINAL ARTICLE

Rivaroxaban in Peripheral Artery Disease after Revascularization

Marc P. Bonaca, M.D., M.P.H., Rupert M. Bauersachs, M.D., Sonia S. Anand, M.D., E. Sebastian Debus, M.D., Ph.D., Mark R. Nehler, M.D., Manesh R. Patel, M.D., Fabrizio Fanelli, M.D., Warren H. Capell, M.D., Lihong Diao, M.D., Nicole Jaeger, M.S., Connie N. Hess, M.D., M.H.S., Akos F. Pap, M.Sc., John M. Kittelson, Ph.D., Ivan Gudz, M.D., Ph.D., Lajos Mátyás, M.D., Dainis K. Krievins, M.D., Rafael Diaz, M.D., Marianne Brodmann, M.D., Eva Muehlhofer, M.D., Lloyd P. Haskell, M.D., Scott D. Berkowitz, M.D., and William R. Hiatt, M.D.



1. To determine the annual number of patients with PAD who undergo lower-limb revascularization (*PAD revascularized population*) in France
2. To identify the proportion of the *PAD revascularized population* which could benefit from Dual Pathway Inhibition (DPI)* (*Voyager-like population*)
3. To assess the onset of major thrombotic vascular events in the 2 populations

*DPI: low-dose rivaroxaban 2.5 mg b.i.d and aspirin 100 mg o.d.



Study design

Retrospective observational study


Data source

The exhaustive French Hospital Discharge Database (PMSI)


Study periods



Number of patients




Revascularization mode




Patient characteristics at inclusion

	PAD-revascularization population	Voyager-like population
Mean age	72.0 years old	69.4 years old
Men	69%	70%
Diabetes	34%	26%
Chronic heart disease	29%	20%
Renal failure	15%	5%
PAD history	33%	24%
Peripheral revascularization history	8%	7%

Cumulative incidence of first major thrombotic vascular event




Major thrombotic vascular events



This study


Cumulative incidence of first event - Curve



at risk 66715 55079 50274 46524 42873 37673 32432 28229 24335 19739 16083

12 713 patients sont à risque à 1 096 jours

Voyager trial



No. at Risk
Placebo

3278 3030 2881 2773 2151 1351 642

This study provides a comprehensive and contemporary overview of patients treated by revascularization for PAD in our country.

Adjusted comparative results will allow to compare these occurrences between the different groups of interest.



Thank you for your attention

Dr Victor Aboyans vaboyans@live.fr